Jun Feng1, Xuefeng Sun2. 1. Department of Hematology, Peking Union Medical College Hospital, Beijing, 100730, China. 2. Department of Respiratory Medicine, Peking Union Medical College Hospital, Beijing, China. sunxfer@sina.com.
Abstract
PURPOSE: Little is known about risk factors for the outcome of pulmonary mucormycosis. We summarized characteristics of this rare disease, and systemically explored risk factors for the outcome. METHODS: Ninety-two patients with pulmonary mucormycosis, including 12 patients at Peking Union Medical College Hospital and 80 patients published in 62 articles between 2006 and 2016, were retrospectively analyzed. RESULTS: The median age was 47.5 years, and the male to female ratio was 2.8:1. Hematological disorders, diabetes mellitus, renal insufficiency and organ transplantation were main underlying conditions. Twelve percent of patients had no underlying diseases. A predilection for involvement of upper lobes was noted, and thick-walled cavity was described in 37.0% of patients on chest computed tomography. Most of the patients were diagnosed by microscopic analysis (95.7%), mainly histopathology; and only a minority were diagnosed by culture of sterile materials (28.3%). The overall mortality rate was 30.4%. Four independent determinants were associated with a better prognosis: hemoptysis (adjusted OR 7.910; 95% CI 1.411-44.342), chronic onset (adjusted OR 25.269, 95% CI 1.654-385.993), treated with medicine (adjusted OR 53.896, 95% CI 3.072-945.561), and treated with surgery (adjusted OR 5.983, 95% CI 1.497-23.918). CONCLUSIONS: Pulmonary mucormycosis is a rare infection with a high mortality. Invasive approach for histopathology and culture are crucial for a definite diagnosis. Acute onset patients had a poorer prognosis, and early treatment with antifungal therapy is imperative. Surgical approach is recommended in appropriate patients for a better outcome.
PURPOSE: Little is known about risk factors for the outcome of pulmonary mucormycosis. We summarized characteristics of this rare disease, and systemically explored risk factors for the outcome. METHODS: Ninety-two patients with pulmonary mucormycosis, including 12 patients at Peking Union Medical College Hospital and 80 patients published in 62 articles between 2006 and 2016, were retrospectively analyzed. RESULTS: The median age was 47.5 years, and the male to female ratio was 2.8:1. Hematological disorders, diabetes mellitus, renal insufficiency and organ transplantation were main underlying conditions. Twelve percent of patients had no underlying diseases. A predilection for involvement of upper lobes was noted, and thick-walled cavity was described in 37.0% of patients on chest computed tomography. Most of the patients were diagnosed by microscopic analysis (95.7%), mainly histopathology; and only a minority were diagnosed by culture of sterile materials (28.3%). The overall mortality rate was 30.4%. Four independent determinants were associated with a better prognosis: hemoptysis (adjusted OR 7.910; 95% CI 1.411-44.342), chronic onset (adjusted OR 25.269, 95% CI 1.654-385.993), treated with medicine (adjusted OR 53.896, 95% CI 3.072-945.561), and treated with surgery (adjusted OR 5.983, 95% CI 1.497-23.918). CONCLUSIONS:Pulmonary mucormycosis is a rare infection with a high mortality. Invasive approach for histopathology and culture are crucial for a definite diagnosis. Acute onset patients had a poorer prognosis, and early treatment with antifungal therapy is imperative. Surgical approach is recommended in appropriate patients for a better outcome.
Entities:
Keywords:
Amphotericin B; Computed tomography; Lung; Mucormycosis; Surgery
Authors: L Pagano; C G Valentini; B Posteraro; C Girmenia; C Ossi; A Pan; A Candoni; A Nosari; M Riva; C Cattaneo; F Rossini; L Fianchi; M Caira; M Sanguinetti; G P Gesu; G Lombardi; N Vianelli; M Stanzani; E Mirone; G Pinsi; F Facchetti; N Manca; L Savi; M Mettimano; V Selva; I Caserta; P Scarpellini; G Morace; A D'Arminio Monforte; P Grossi; D Giudici; A M Tortorano; A Bonini; L Ricci; M Picardi; F Rossano; R Fanci; P Pecile; L Fumagalli; L Ferrari; P L Capecchi; C Romano; A Busca; A Barbui; M Garzia; R R Minniti; G Farina; M T Montagna; F Bruno; O Morelli; A Chierichini; P M Placanica; E Castagnola; R Bandettini; S Giordano; R Monastero; M E Tosti; M R Rossi; P Spedini; R Piane; M Nucci; F Pallavicini; M Bassetti; F Cristini; M LA Sorda; M Viviani Journal: J Chemother Date: 2009-06 Impact factor: 1.714
Authors: Ruth von Scheven; Pia Lebiedz; Tilmann Spieker; Andreas Uekoetter; Wolfgang E Berdel; Torsten Kessler Journal: Mycoses Date: 2011-09-13 Impact factor: 4.377
Authors: Ben De Pauw; Thomas J Walsh; J Peter Donnelly; David A Stevens; John E Edwards; Thierry Calandra; Peter G Pappas; Johan Maertens; Olivier Lortholary; Carol A Kauffman; David W Denning; Thomas F Patterson; Georg Maschmeyer; Jacques Bille; William E Dismukes; Raoul Herbrecht; William W Hope; Christopher C Kibbler; Bart Jan Kullberg; Kieren A Marr; Patricia Muñoz; Frank C Odds; John R Perfect; Angela Restrepo; Markus Ruhnke; Brahm H Segal; Jack D Sobel; Tania C Sorrell; Claudio Viscoli; John R Wingard; Theoklis Zaoutis; John E Bennett Journal: Clin Infect Dis Date: 2008-06-15 Impact factor: 9.079
Authors: Driele Peixoto; Sarah P Hammond; Nicolas C Issa; Rachna Madan; Ritu R Gill; Danny A Milner; Yolonda L Colson; Sophia Koo; Lindsey R Baden; Francisco M Marty Journal: Open Forum Infect Dis Date: 2014-05-12 Impact factor: 3.835
Authors: Kathleen P Hartnett; Brendan R Jackson; Kiran M Perkins; Janet Glowicz; Janna L Kerins; Stephanie R Black; Shawn R Lockhart; Bryan E Christensen; Karlyn D Beer Journal: J Fungi (Basel) Date: 2019-07-24